TCL Archive As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data. October 22, 2004
TCL Archive Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint May 31, 2013
TCL Archive In odd aftermath of FDA Commissioner Mark McClellan’s lecture, NCI Director Andrew von Eschenbach forwards the commissioner’s thank-you note to 3,000 NCI staff. The email blast follows FDA’s return of NCI’s gift to McClellan. March 12, 2004
